Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 23

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jun 21, 2008; 14(23): 3750-3753
Published online Jun 21, 2008. doi: 10.3748/wjg.14.3750

Table 1 Characteristics of patients (n = 104)

Characteristics	Data, n (%)
Age (yr)	59 ± 9 (mean ± SD)
Sex
Male	72 (69.2)
Female	32 (30.8)
Location of tumors
Head	86 (82.7)
Body	8 (7.7)
Body and tail	10 (9.6)
Type of operation
Pancreaticoduodenectomy	48 (46.2)
Distal pancreatectomy	10 (9.6)
Exploratory laparotomy and biopsy	46 (44.2)

Citation: Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008; 14(23): 3750-3753
URL: https://www.wjgnet.com/1007-9327/full/v14/i23/3750.htm
DOI: https://dx.doi.org/10.3748/wjg.14.3750

Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008; 14(23): 3750-3753 [PMID: 18595144 DOI: 10.3748/wjg.14.3750]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.